Scotiabank reiterates AST SpaceMobile stock underperform on mission concerns By Investing.com

AST SpaceMobile’s BlueBird 7 satellite failed to deploy in a usable orbit after the New Glenn launch, and the company expects the satellite to de-orbit while recovering the cost through insurance. Scotiabank reiterated a Sell rating with a $41.20 price target, the low end of Wall Street’s range, after the stock fell to $78.52 from $90.94 and was down 13.6% over the past week. The article also notes mixed analyst views, with Deutsche Bank cutting its target to $117 and Barclays raising its target to $65.

Analysis

The market is starting to price ASTS less like a pre-commercial satellite story and more like a program-execution equity, where each launch anomaly compounds the discount rate on the entire constellation roadmap. The core second-order effect is not the direct loss of one satellite, but the probability that launch partners, insurers, and customers all re-price ASTS’s timeline risk upward, which can compress multiple expansion even if near-term cash loss is covered.

This is also a relative-value event across the connectivity stack. A slower ASTS deployment cadence is an incremental positive for alternate terrestrial coverage and for any operator with more mature spectrum, backhaul, or enterprise connectivity monetization, while the biggest loser is likely ASTS’s own cost of capital rather than its 2026 revenue line. If deployments slip by even 1-2 quarters, the market may push out meaningful commercial ramp assumptions by a full year because network effects and customer commitments are tied to constellation density, not isolated asset recovery.

The bearish consensus may be overextending on the immediate stock reaction but still underestimating the medium-term damage to financing optionality. Insurance limits the balance-sheet hit, yet it does not insure away schedule slippage, vendor scrutiny, or launch-partner caution; those are the variables that can matter most over the next 3-6 months. META’s constructive posture is a counterpoint, but it is not a near-term catalyst unless it converts into commercial commitments or funding support, which would be the cleanest way to reset sentiment.

The real contrarian setup is that this is not a binary ‘satellite failed, stock should halve’ event; it is a timing and credibility event. If ASTS can show a clean subsequent launch window and no broader platform issue within the next 4-8 weeks, the stock could retrace sharply because a lot of the panic is about program contamination rather than asset loss. Absent that, each incremental delay likely widens the gap between headline partnerships and monetizable capacity.

Key Decisions for Investors

• Short ASTS into strength over the next 1-3 sessions; use rallies toward prior support as entry, targeting a 15-25% downside move if launch uncertainty persists, with tight risk above any confirmed recovery timetable.
• Pair trade: long GSAT / short ASTS for the next 1-2 months to express relative deployment-execution risk; thesis is that capital migrates toward the operator with less binary launch dependence and lower event risk.
• Buy ASTS put spreads 1-2 expiries out rather than outright puts to capture another leg lower if management guidance slips, while capping premium burn if insurance and a quick relaunch stabilize sentiment.
• Avoid chasing DB or BCS on this headline; use any weakness in ASTS-linked financing perception as a signal to reduce exposure to the more levered, higher-beta supplier/peer basket.
• If ASTS announces a clean follow-on launch or concrete partner commitment within 4-8 weeks, cover shorts quickly; the stock is likely to squeeze hard because current positioning is already leaning negative.